STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation (NCT04428944) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation
United States, Australia617 participantsStarted 2021-06-01
Plain-language summary
The objective of this study is to compare the efficacy of three different ablation strategies in patients with persistent AF:
1. PV antral isolation alone (PVAI)
2. PV antral isolation plus ablation of drivers (PVAI+drivers)
3. PV antral isolation plus isolation of posterior wall (PVAI+box) All three strategies will employ contemporary catheter ablation technology using more efficient open irrigated tip cooling and contact force sensing.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients 18 years of age or older
✓. Patients undergoing first-time ablation procedure for AF
✓. Patients with persistent AF defined as a sustained episode more than 3 months but less than three years
✓. Patients with symptomatic AF - symptomatic patients are those who have been aware of their AF at any time within the last 5 years prior to enrolment. Symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, left ventricular dysfunction, or other symptoms or any combination of the above
✓. Patients whose AF has been refractory to at least one antiarrhythmic drug
✓. At least one episode of AF must have been documented by ECG, holter, loop recorder, telemetry, trans-telephonic monitor or implanted device within the last 2 years from enrolment
✓. Patients must be able and willing to provide written informed consent to participate in the study
Exclusion criteria
✕. Patients with paroxysmal AF (no episodes lasting \> 7 days)
✕. Patients with early persistent AF, sustained episode ≤ 3 months
✕. Patients with very long lasting persistent AF (episodes lasting \> 3 years)
✕. Patients with CHA2DS2-VASc score of 0.
✕
What they're measuring
1
Freedom from documented atrial arrhythmia ≥ 30 seconds at 18 months after one ablation procedure on or off antiarrhythmic medications (AAM).
Timeframe: 18 months
Trial details
NCT IDNCT04428944
SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre